Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
Matsumoto K, Takayama N, Aisa Y, Ueno H, Hagihara M, Watanabe K, Nakaya A, Chen K, Shimizu T, Tsukada Y, Yamada Y, Nakazato T, Ishida A, Miyakawa Y, Yokoyama K, Nakajima H, Masuda Y, Yano T, Okamoto S; Keio BRB Study Group. Matsumoto K, et al. Among authors: nakazato t. Int J Hematol. 2015 Jun;101(6):554-62. doi: 10.1007/s12185-015-1767-3. Epub 2015 Mar 19. Int J Hematol. 2015. PMID: 25783753 Clinical Trial.
Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
Ozaki S, Hata H, Abe M, Saitoh T, Hanamura I, Yano H, Sunami K, Kosugi H, Sawamura M, Nakazato T, Masunari T, Mori M, Takagi T, Murakami H, Shimizu K. Ozaki S, et al. Among authors: nakazato t. Ann Hematol. 2016 May;95(6):921-9. doi: 10.1007/s00277-016-2661-7. Epub 2016 Apr 5. Ann Hematol. 2016. PMID: 27044390 Clinical Trial.
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Nakazato T, Hagihara M, Sahara N, Tamai Y, Ishii R, Tamaki S, Wake A, Tajika K, Sakai R, Kobayashi T, Hua J, Inoue M, Aisa Y, Fujisawa S, Miyazaki K, Irie S, Tanaka E, Higashihara M. Nakazato T, et al. Ann Hematol. 2021 Nov;100(11):2745-2754. doi: 10.1007/s00277-021-04592-y. Epub 2021 Jul 31. Ann Hematol. 2021. PMID: 34333665 Clinical Trial.
Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromes.
Ueda Y, Usuki K, Fujita J, Matsumura I, Aotsuka N, Sekiguchi N, Nakazato T, Iwasaki H, Takahara-Matsubara M, Sugimoto S, Goto M, Naoe T, Kizaki M, Miyazaki Y, Aakashi K. Ueda Y, et al. Among authors: nakazato t. Cancer Sci. 2022 Apr;113(4):1377-1392. doi: 10.1111/cas.15245. Epub 2022 Mar 9. Cancer Sci. 2022. PMID: 34932235 Free PMC article. Clinical Trial.
[CD4-positive diffuse large B-cell lymphoma].
Nakazato T, Suzuki K, Mihara A, Sanada Y, Kakimoto T, Yoshida S. Nakazato T, et al. Rinsho Ketsueki. 2009 Jul;50(7):568-73. Rinsho Ketsueki. 2009. PMID: 19638725 Japanese.
334 results